Dashboard
1
The company has declared Positive results for the last 18 consecutive quarters
- NET SALES(9M) At CNY 2,289.64 MM has Grown at 32.13%
- NET PROFIT(9M) At CNY 705.37 MM has Grown at 47.07%
- RAW MATERIAL COST(Y) Fallen by -0.75% (YoY)
2
With ROE of 34.50%, it has a fair valuation with a 11.63 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 32,048 Million (Large Cap)
34.00
NA
0.79%
-0.24
34.50%
11.63
Revenue and Profits:
Net Sales:
833 Million
(Quarterly Results - Jun 2025)
Net Profit:
246 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.88%
0%
-3.88%
6 Months
8.95%
0%
8.95%
1 Year
11.57%
0%
11.57%
2 Years
74.48%
0%
74.48%
3 Years
111.87%
0%
111.87%
4 Years
185.84%
0%
185.84%
5 Years
105.74%
0%
105.74%
Xiamen Amoytop Biotech Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
32.36%
EBIT Growth (5y)
49.44%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
1.11
Tax Ratio
10.37%
Dividend Payout Ratio
30.48%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
40.89%
ROE (avg)
22.33%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
11.63
EV to EBIT
30.11
EV to EBITDA
27.41
EV to Capital Employed
15.01
EV to Sales
10.05
PEG Ratio
0.74
Dividend Yield
0.79%
ROCE (Latest)
49.85%
ROE (Latest)
34.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
833.10
669.90
24.36%
Operating Profit (PBDIT) excl Other Income
298.90
238.10
25.54%
Interest
0.30
0.10
200.00%
Exceptional Items
0.60
0.00
Consolidate Net Profit
245.80
182.10
34.98%
Operating Profit Margin (Excl OI)
326.90%
315.80%
1.11%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 24.36% vs -21.95% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 34.98% vs -33.42% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,803.40
2,089.10
34.19%
Operating Profit (PBDIT) excl Other Income
1,023.40
727.70
40.63%
Interest
0.60
0.80
-25.00%
Exceptional Items
0.90
-10.10
108.91%
Consolidate Net Profit
827.60
555.40
49.01%
Operating Profit Margin (Excl OI)
331.70%
315.70%
1.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 34.19% vs 37.52% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 49.01% vs 93.52% in Dec 2023
About Xiamen Amoytop Biotech Co. Ltd. 
Xiamen Amoytop Biotech Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






